ICYMI, this week we had stories from the 2022 Fall Clinical Dermatology Conference for PAs & NPs, FDA's approval of dupilumab, and more.
April Armstrong, MD, MPH, highlights her recommendations for improving patients’ outcomes, engagement, and satisfaction as part of a panel presentation at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.
A poster presented at the current 2022 Fall Clinical Dermatology Conference for PAs & NPs showed normalization of skin barrier function in patients with moderate to severe atopic dermatitis taking dupilumab, according to the investigators.
In a hard-hitting session from the 2022 Fall Clinical Dermatology Conference for PAs & NPs, April Armstrong, MD, MPH, dove into PAD technology and future innovations in psoriasis treatment.
Will drinking caffeinated coffee reduce skin cancer risk? Is gene expression profiling set to become mainstream testing for melanoma? See what Darrell S. Rigel, MD, MS, FAAD, has to say.
New synthetic small molecule aims to counter drug resistance in BRAF-mutated melanomas.
In a video with Dermatology Times®, James Q. Del Rosso, DO, discusses his presentation “What’s News in the Medicine Chest” at the current 2022 Fall Clinical Dermatology Conference for PAs & NPs.
A look at the types of visits and treatments prescribed via teledermatology during the pandemic reinforces the staying power of virtual acne care; statistics offer key details.
Authors suggest not practice changes but more research.
Darrell S. Rigel, MD, MS, delves into the power and potential of precision medicine in diagnosis, prognosis and therapy selection.
A common complaint in puberty, hormonal acne also affects skin health and quality of life for adults of all genders, driving the need for new solutions.
Kenneth J. Tomecki, MD, discussed the clinical relevance of sexually transmitted diseases (STDs) to dermatology and outlined what to look for and how to treat various conditions at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.
In a session for the 2022 Fall Clinical Dermatology Conference for PAs & NPs, held June 3 to 5, in Scottsdale, Arizona, James Q. Del Rosso, DO, delves into new knowledge on the characteristics of this challenging skin condition.
Darrell S. Rigel, MD, MS, FAAD, answers the question of what is up coming in the world of dermatology in the way of precision medicine.
About 80% of patients treated with roflumilast foam 0.3% (ARQ-154, Arcutis Biotherapeutics Inc) met the primary endpoint of the trial.
James Q. Del Rosso, DO, highlights different rosacea treatment options in his session at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.
Education, honesty, and communication skills are key for both patient and dermatologist when it comes to creating treatment regimens.
Speaking at the 2022 Fall Clinical Dermatology Conference for PAs & NPs, Joshua Zeichner, MD, cut through marketing hype and misperceptions of patients to assess products that bridge cosmetics and medicine.
Joshua Zeichner, MD, discusses how important it is to treat acne properly and gives a tip about moisturizers and topical retinoids.
Recent research puts the role of sunscreens in a whole new light. Roger Ceilley MD, FAAD, FACMS outlined need-to-know information on SPF, how to improve adherence and address patient concerns about sunscreen safety and more at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.
Advances ranging from combined laser and drug therapies to innovative devices mean patients with acne no longer have to be scared of permanent scarring.
Pediatric patients taking 4 or more medications were more likely to experience medication errors.
Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis.
In this week’s Pointers with Dr Portela, the 208SkinDoc talks about the end of Melanoma Awareness Month and gives advice on how to prevent skin cancer.
This painful skin disease may lower the odds of live birth and trigger comorbidities.
Age alone does not appear to predict all post-treatment outcomes for BCC patients and should not be used solely to guide BCC-related treatment decisions, a recent study says.
The providers in our clinic want to start billing e-visits. Can they bill for all the communication between the provider and patient through our online portal?
A systematic review of literature shows a shift from amputation to other surgical tactics to treat certain types of nail squamous cell carcinomas.
A recent study dove into how precision medicine can be used to better target inflammatory skin disease and provide physicians with better treatment regimens.
The most critical step is understanding what value precision medicine brings to your practice, and where it can have greatest impact from both a clinical and business perspective.